Christiane Marth - Gynecology

Author Information

Christiane Marth is affiliated with the Department of Obstetrics and Gynecology at the Medical University Innsbruck, located in Innsbruck, Austria. Her research primarily focuses on gynecological oncology, with significant contributions to the understanding and treatment of ovarian and endometrial cancers.

Research Contributions

Christiane Marth has significantly advanced the field of gynecological oncology through numerous high-impact research studies. In 2022, she contributed to understanding the real-world effects of bevacizumab in newly diagnosed epithelial ovarian cancer and evaluated the dubious effects of methadone as an "anticancer" drug on ovarian cancer cell lines. In 2021, she was involved in multiple pivotal Phase 3 trials, including studies on pembrolizumab and lenvatinib for advanced endometrial cancer, pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer, and alpelisib plus olaparib for platinum-resistant high-grade serous ovarian cancer. Additionally, her work extended to the impact of the COVID-19 pandemic on cancer detection rates and various other clinical trials aimed at improving cancer treatment outcomes.

Aliases

Christiane Marth is also known by several aliases, including C. Marth, Ch. Marth, C H Marth, Christian Marth, and Ch Marth.

Publication and Citation Metrics

Metric	Value
Total Papers	645
Total Citations	25,341
H-Index	73